Richard L Attanoos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard L Attanoos has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
A R Gibbs
Department of Histopathology, Cardiff and Vale NHS Trust, Llandough Hospital, Cardiff, UK
4 shared publicationsD H Thomas
Department of Histopathology, Llandough Hospital, Cardiff and Vale NHS Trust, Penarth, South Glamorgan, Wales, UK
2 shared publicationsA Griffin
Department of Histopathology, Llandough Hospital, Cardiff and Vale NHS Trust, Penarth, Cardiff, Wales, UK
1 shared publicationA M Boyde
Department of Histopathology, Llandough Hospital, Cardiff and Vale NHS Trust, Penarth, UK e‐mail
1 shared publication- A R Gibbs
Department of Histopathology, Llandough Hospital, Cardiff and Vale NHS Trust, Penarth, South Glamorgan, Wales, UK
1 shared publication Allen R Gibbs
Department of Histopathology, University Hospital Llandough, Cardiff and Vale NHS Trust, Penarth, Wales, UK
1 shared publication
Latest Publications
- Open Access
- 1 January 2009
- Published by Wiley in Histopathology
- Vol. 54 (1) , 134-142
An approach to industrial post mortems
Industrial-related deaths represent a specialized aspect of autopsy practice. The purpose of this review is to assist the pathologist in the handling of such deaths. The diseases associated with the three most significant mineral dusts (asbestos, coal and silica) are described, together with a selection of less well-known mineral dust diseases. This review addresses the complex issues of ascribing disease to industrial exposures and the role of mineral analysis. The authors discuss the common medical legal issues that are encountered at post mortem and at inquest deposition.
- 1 January 2009
- Published by Wiley in Histopathology
- Vol. 54 (1) , 134-142
Open AccessAn approach to industrial post mortems
Industrial-related deaths represent a specialized aspect of autopsy practice. The purpose of this review is to assist the pathologist in the handling of such deaths. The diseases associated with the three most significant mineral dusts (asbestos, coal and silica) are described, together with a selection of less well-known mineral dust diseases. This review addresses the complex issues of ascribing disease to industrial exposures and the role of mineral analysis. The authors discuss the common medical legal issues that are encountered at post mortem and at inquest deposition.
- 20 August 2008
- Published by Wiley in Histopathology
- Vol. 53 (3) , 340-344
The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma
Aims: To evaluate the diagnostic accuracy of closed and open pleural biopsies in diagnosing malignant pleural mesothelioma.Methods and results: The autopsy study group comprised 45 malignant mesotheliomas. All prior pleural biopsy investigations were reviewed. Forty‐one of 45 (91%) had had an antemortem diagnosis of malignant mesothelioma. In these 41 cases, 57 prior diagnostic pleural biopsies had been performed [36 closed needle biopsies: 31 blind; five computed tomography (CT)‐guided and 21 open pleural biopsies]. For definitive diagnosis open pleural biopsy yielded a sensitivity of 95% and specificity of 100%. For definitive diagnosis closed blind pleural biopsies yielded a sensitivity of 16% and specificity of 94%. Thirty‐two per cent of ‘blind’ biopsies were inadequate. CT‐guided pleural biopsies yielded a definitive diagnostic accuracy of 100% (5/5). Biopsy specimen size was important in obtaining a positive definitive diagnosis. Diagnosis was attained in 75% of specimens >10 mm in size compared with 8% Conclusions: Overall, all procedures had utility but definitive diagnostic accuracy for ‘blind’ closed pleural biopsy was low (16%), dependent on biopsy specimen size and tumour subtype. Sarcomatoid subtype malignant mesothelioma yielded the lowest diagnostic accuracy. For all subtypes of malignant mesothelioma, open pleural biopsy produced the highest diagnostic accuracy (100% sensitivity, 95% specificity).
- 20 August 2008
- Published by Wiley in Histopathology
- Vol. 53 (3) , 340-344
The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma
Aims: To evaluate the diagnostic accuracy of closed and open pleural biopsies in diagnosing malignant pleural mesothelioma.Methods and results: The autopsy study group comprised 45 malignant mesotheliomas. All prior pleural biopsy investigations were reviewed. Forty‐one of 45 (91%) had had an antemortem diagnosis of malignant mesothelioma. In these 41 cases, 57 prior diagnostic pleural biopsies had been performed [36 closed needle biopsies: 31 blind; five computed tomography (CT)‐guided and 21 open pleural biopsies]. For definitive diagnosis open pleural biopsy yielded a sensitivity of 95% and specificity of 100%. For definitive diagnosis closed blind pleural biopsies yielded a sensitivity of 16% and specificity of 94%. Thirty‐two per cent of ‘blind’ biopsies were inadequate. CT‐guided pleural biopsies yielded a definitive diagnostic accuracy of 100% (5/5). Biopsy specimen size was important in obtaining a positive definitive diagnosis. Diagnosis was attained in 75% of specimens >10 mm in size compared with 8% Conclusions: Overall, all procedures had utility but definitive diagnostic accuracy for ‘blind’ closed pleural biopsy was low (16%), dependent on biopsy specimen size and tumour subtype. Sarcomatoid subtype malignant mesothelioma yielded the lowest diagnostic accuracy. For all subtypes of malignant mesothelioma, open pleural biopsy produced the highest diagnostic accuracy (100% sensitivity, 95% specificity).
- 1 November 2004
- Published by Wiley in Histopathology
- Vol. 45 (5) , 540-542
Coexistent atypical adenomatous hyperplasia, primary lung adenocarcinoma and pleural mesothelioma in an asbestos-exposed subject
- 1 November 2004
- Published by Wiley in Histopathology
- Vol. 45 (5) , 540-542
Coexistent atypical adenomatous hyperplasia, primary lung adenocarcinoma and pleural mesothelioma in an asbestos-exposed subject
- 27 October 2003
- Published by Wiley in Histopathology
- Vol. 43 (5) , 444-452
‘Pseudomesotheliomatous’ carcinomas of the pleura: a 10‐year analysis of cases from the Environmental Lung Disease Research Group, Cardiff
Aims: To undertake a clinicopathological study of diffuse serosal neoplasms of epithelial histogenesis which clinically and pathologically mimic malignant pleural mesothelioma.Methods and results: Over a 10‐year (1990–2000) study period 53 carcinomas mimicking diffuse pleural mesothelioma (‘pseudomesotheliomatous’ carcinoma) were identified. The study group comprised 50 men and three females, age range 33–77 (median 68) years. In 46 (87%) cases there was a history of smoking and in 40 (76%) cases a history of asbestos exposure. Histologically the pleural ‘pseudomesotheliomatous’ carcinomas could be divided into two broad groups: primary pulmonary carcinomas with florid pleurotropic growth (n = 47), of which 34 (70%) were adenocarcinomas; and diffuse carcinomatous involvement of the pleura by metastatic tumour (n = 6). This latter group comprised two transitional cell carcinomas of bladder, one renal (clear) cell carcinoma, one ductal pancreatic adenocarcinoma, one prostatic adenocarcinoma and one squamous cell carcinoma of parotid gland origin. Follow‐up data were available in 35 cases. Regardless of tumour type, survival was poor (median 8 months) and comparable to diffuse pleural mesothelioma.Conclusions: Pleural ‘pseudomesotheliomatous’ carcinomas are uncommon (comprising 6% of referrals), pathologically heterogeneous tumours with poor prognosis. Tissue diagnosis should be obtained in all cases of suspected diffuse pleural neoplasia. By light microscopy and immunophenotype many of the tumours mimicked malignant mesothelioma. In particular, an awareness that all neoplasms exhibiting squamous differentiation may express cytokeratin 5/6 and thrombomodulin is important to prevent misinterpretation. In this respect, calretinin is regarded as the most specific and sensitive mesothelial marker. Misdiagnosis may have medico–legal implications in asbestos‐related compensation claims.
- 27 October 2003
- Published by Wiley in Histopathology
- Vol. 43 (5) , 444-452
‘Pseudomesotheliomatous’ carcinomas of the pleura: a 10‐year analysis of cases from the Environmental Lung Disease Research Group, Cardiff
Aims: To undertake a clinicopathological study of diffuse serosal neoplasms of epithelial histogenesis which clinically and pathologically mimic malignant pleural mesothelioma.Methods and results: Over a 10‐year (1990–2000) study period 53 carcinomas mimicking diffuse pleural mesothelioma (‘pseudomesotheliomatous’ carcinoma) were identified. The study group comprised 50 men and three females, age range 33–77 (median 68) years. In 46 (87%) cases there was a history of smoking and in 40 (76%) cases a history of asbestos exposure. Histologically the pleural ‘pseudomesotheliomatous’ carcinomas could be divided into two broad groups: primary pulmonary carcinomas with florid pleurotropic growth (n = 47), of which 34 (70%) were adenocarcinomas; and diffuse carcinomatous involvement of the pleura by metastatic tumour (n = 6). This latter group comprised two transitional cell carcinomas of bladder, one renal (clear) cell carcinoma, one ductal pancreatic adenocarcinoma, one prostatic adenocarcinoma and one squamous cell carcinoma of parotid gland origin. Follow‐up data were available in 35 cases. Regardless of tumour type, survival was poor (median 8 months) and comparable to diffuse pleural mesothelioma.Conclusions: Pleural ‘pseudomesotheliomatous’ carcinomas are uncommon (comprising 6% of referrals), pathologically heterogeneous tumours with poor prognosis. Tissue diagnosis should be obtained in all cases of suspected diffuse pleural neoplasia. By light microscopy and immunophenotype many of the tumours mimicked malignant mesothelioma. In particular, an awareness that all neoplasms exhibiting squamous differentiation may express cytokeratin 5/6 and thrombomodulin is important to prevent misinterpretation. In this respect, calretinin is regarded as the most specific and sensitive mesothelial marker. Misdiagnosis may have medico–legal implications in asbestos‐related compensation claims.
- 26 September 2003
- Published by Wiley in Histopathology
- Vol. 43 (4) , 387-392
Synchronous diffuse malignant mesothelioma and carcinomas in asbestos‐exposed individuals
Aims: The development of synchronous diffuse malignant mesothelioma and carcinoma in individuals exposed to asbestos is rare. We report nine cases and discuss the medico–legal implications.Methods and results: Five hundred patients seeking compensation for asbestos‐related diffuse malignant mesothelioma were reviewed with access to post‐mortem data. The study group comprised cases in which a second (non‐mesothelial) neoplasm was identified. The study group comprised eight males, one female, mean age 68 years (range 60–75). All individuals gave a history of asbestos exposure. Synchronous malignant mesothelioma with carcinoma was identified in 9/500 (1.8%). Eight malignant mesotheliomas were pleural, one was primary peritoneal in origin. By morphological subtyping there were four epithelioid, three biphasic and two sarcomatoid mesotheliomas. In 6/9 (67%) the second tumour was a primary bronchogenic carcinoma (three adenocarcinomas, two squamous cell carcinomas and one small‐cell carcinoma). In 3/9 (33%) the second tumour was a non‐bronchogenic carcinoma (colonic, pancreatic and breast ductal adenocarcinoma). No other neoplasms were identified in the cohort of malignant mesotheliomas studied. Five persons had pathological evidence of asbestosis (four had bronchogenic carcinomas, one colorectal adenocarcinoma). Two persons with non‐bronchogenic carcinomas had identifiable asbestos bodies but no interstitial fibrosis. In two cases the second neoplasms (primary bronchogenic squamous cell and small‐cell carcinomas) were associated with diffuse interstitial fibrosis but no asbestos bodies were seen on light microscopy. In each case transmission electron microscopic mineral analysis revealed an asbestos fibre burden within the background population range for control subjects and well below that seen in cases of established asbestosis. These cases were considered to represent cryptogenic fibrosing alveolitis in subjects with a history of asbestos exposure.Conclusions: Synchronous malignant mesothelioma with carcinomas in asbestos‐exposed workers is rare and identified in 1.8% of 500 malignant mesotheliomas in this series. In most cases the carcinoma represents a primary bronchogenic neoplasm. Primary lung carcinomas are recognized to be asbestos related only when occurring in association with asbestosis. In this series this combination (bronchogenic carcinoma and asbestosis) was seen in four (0.8%) cases. In post‐mortem cases for possible malignant mesothelioma it is important to identify any other neoplasia and determine whether it is related to asbestos. Their presence impact upon anticipated life expectancy and in the presence of malignant mesothelioma will affect the compensation settlement.
- 26 September 2003
- Published by Wiley in Histopathology
- Vol. 43 (4) , 387-392
Synchronous diffuse malignant mesothelioma and carcinomas in asbestos‐exposed individuals
Aims: The development of synchronous diffuse malignant mesothelioma and carcinoma in individuals exposed to asbestos is rare. We report nine cases and discuss the medico–legal implications.Methods and results: Five hundred patients seeking compensation for asbestos‐related diffuse malignant mesothelioma were reviewed with access to post‐mortem data. The study group comprised cases in which a second (non‐mesothelial) neoplasm was identified. The study group comprised eight males, one female, mean age 68 years (range 60–75). All individuals gave a history of asbestos exposure. Synchronous malignant mesothelioma with carcinoma was identified in 9/500 (1.8%). Eight malignant mesotheliomas were pleural, one was primary peritoneal in origin. By morphological subtyping there were four epithelioid, three biphasic and two sarcomatoid mesotheliomas. In 6/9 (67%) the second tumour was a primary bronchogenic carcinoma (three adenocarcinomas, two squamous cell carcinomas and one small‐cell carcinoma). In 3/9 (33%) the second tumour was a non‐bronchogenic carcinoma (colonic, pancreatic and breast ductal adenocarcinoma). No other neoplasms were identified in the cohort of malignant mesotheliomas studied. Five persons had pathological evidence of asbestosis (four had bronchogenic carcinomas, one colorectal adenocarcinoma). Two persons with non‐bronchogenic carcinomas had identifiable asbestos bodies but no interstitial fibrosis. In two cases the second neoplasms (primary bronchogenic squamous cell and small‐cell carcinomas) were associated with diffuse interstitial fibrosis but no asbestos bodies were seen on light microscopy. In each case transmission electron microscopic mineral analysis revealed an asbestos fibre burden within the background population range for control subjects and well below that seen in cases of established asbestosis. These cases were considered to represent cryptogenic fibrosing alveolitis in subjects with a history of asbestos exposure.Conclusions: Synchronous malignant mesothelioma with carcinomas in asbestos‐exposed workers is rare and identified in 1.8% of 500 malignant mesotheliomas in this series. In most cases the carcinoma represents a primary bronchogenic neoplasm. Primary lung carcinomas are recognized to be asbestos related only when occurring in association with asbestosis. In this series this combination (bronchogenic carcinoma and asbestosis) was seen in four (0.8%) cases. In post‐mortem cases for possible malignant mesothelioma it is important to identify any other neoplasia and determine whether it is related to asbestos. Their presence impact upon anticipated life expectancy and in the presence of malignant mesothelioma will affect the compensation settlement.
- 27 August 2003
- Published by Wiley in Histopathology
- Vol. 43 (3) , 231-238
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
Aims: To evaluate the expression of the intermediate filament desmin in reactive mesothelium and malignant mesothelioma and to compare its utility with five other previously reported immunomarkers claimed to be of use in distinguishing reactive from neoplastic mesothelium.Methods and results: Sixty cases of malignant pleural mesothelioma and 40 cases of reactive mesothelial hyperplasia formed the study group. Cases were immunohistochemically stained with desmin, epithelial membrane antigen (EMA), p53, Bcl‐2, P‐glycoprotein and platelet‐derived growth factor receptor (PDGF‐R) β‐chain by the avidin–biotin complex method. The cohort of malignant pleural mesotheliomas were immunoreactive to desmin, EMA and p53 in 6/60 (10%), 48/60 (80%) and 27/60 (45%), respectively. In comparison, the cohort of reactive mesothelial hyperplasias were immunoreactive to desmin, EMA and p53 in 34/40 (85%), 8/40 (20%) and 0/40 (0%), respectively. In a smaller cohort (n = 15) of malignant pleural mesotheliomas, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain were expressed in 0/15 (0%), 2/15 (13%) and 15/15 (100%), respectively. In a small cohort (n = 15) of reactive mesothelial hyperplasias, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain were immunoreactive in 0/15 (0%), 0/15 (0%) and 6/15 (40%), respectively.Conclusions: Desmin and EMA appear to be the most useful markers in distinguishing benign from malignant mesothelial proliferations. Desmin appears to be preferentially expressed in reactive mesothelium and EMA appears to be preferentially expressed in neoplastic mesothelium. The complementary use of both markers is advocated in ascertaining the nature of mesothelial proliferations. Immunohistochemical detection of mutated p53 oncoprotein appeared to be of less utility in this study on account of the low marker sensitivity for malignant mesothelioma. However, p53 antibody may be of use as a second‐line marker of neoplastic mesothelium within a standard immunohistochemical panel of antibodies. In this study, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain appear to be of no use in distinguishing reactive from neoplastic mesothelium, although more formal evaluation of these markers is required.
- 27 August 2003
- Published by Wiley in Histopathology
- Vol. 43 (3) , 231-238
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
Aims: To evaluate the expression of the intermediate filament desmin in reactive mesothelium and malignant mesothelioma and to compare its utility with five other previously reported immunomarkers claimed to be of use in distinguishing reactive from neoplastic mesothelium.Methods and results: Sixty cases of malignant pleural mesothelioma and 40 cases of reactive mesothelial hyperplasia formed the study group. Cases were immunohistochemically stained with desmin, epithelial membrane antigen (EMA), p53, Bcl‐2, P‐glycoprotein and platelet‐derived growth factor receptor (PDGF‐R) β‐chain by the avidin–biotin complex method. The cohort of malignant pleural mesotheliomas were immunoreactive to desmin, EMA and p53 in 6/60 (10%), 48/60 (80%) and 27/60 (45%), respectively. In comparison, the cohort of reactive mesothelial hyperplasias were immunoreactive to desmin, EMA and p53 in 34/40 (85%), 8/40 (20%) and 0/40 (0%), respectively. In a smaller cohort (n = 15) of malignant pleural mesotheliomas, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain were expressed in 0/15 (0%), 2/15 (13%) and 15/15 (100%), respectively. In a small cohort (n = 15) of reactive mesothelial hyperplasias, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain were immunoreactive in 0/15 (0%), 0/15 (0%) and 6/15 (40%), respectively.Conclusions: Desmin and EMA appear to be the most useful markers in distinguishing benign from malignant mesothelial proliferations. Desmin appears to be preferentially expressed in reactive mesothelium and EMA appears to be preferentially expressed in neoplastic mesothelium. The complementary use of both markers is advocated in ascertaining the nature of mesothelial proliferations. Immunohistochemical detection of mutated p53 oncoprotein appeared to be of less utility in this study on account of the low marker sensitivity for malignant mesothelioma. However, p53 antibody may be of use as a second‐line marker of neoplastic mesothelium within a standard immunohistochemical panel of antibodies. In this study, Bcl‐2, P‐glycoprotein and PDGF‐R β‐chain appear to be of no use in distinguishing reactive from neoplastic mesothelium, although more formal evaluation of these markers is required.
- 27 August 2003
- Published by Wiley in Histopathology
- Vol. 43 (3) , 303-304
Sister Mary Joseph's nodule in malignant peritoneal mesothelioma
- 27 August 2003
- Published by Wiley in Histopathology
- Vol. 43 (3) , 303-304
Sister Mary Joseph's nodule in malignant peritoneal mesothelioma